{
    "2021-02-20": [
        [
            {
                "time": "",
                "original_text": "【浙商医药|孙建】周报：「恐高」回调，坚守主线",
                "features": {
                    "keywords": [
                        "医药",
                        "周报",
                        "恐高",
                        "回调",
                        "坚守",
                        "主线"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业深度报告：双抗时代 渐入佳境",
                "features": {
                    "keywords": [
                        "医药生物",
                        "行业",
                        "深度报告",
                        "双抗时代",
                        "渐入佳境"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}